Skip to search formSkip to main contentSkip to account menu

deferasirox

Known as: deferasirox [Chemical/Ingredient], 4-(3,5-bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid, 4-(3,5-Bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic Acid 
A drug used to treat too much iron in the blood caused by blood transfusions. It is being studied in the treatment of myelodysplastic syndromes (a… 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (3)

BenzoatesIron Chelating AgentsTriazoles

Narrower (2)

ExjadeICL 670
Iron Chelating Activity [MoA]deferasirox 125 MG Tablet for Oral Suspension [Exjade]deferasirox 360 MG Oral Tablet [Jadenu]deferasirox Oral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).
Randomized comparison data on the efficacy and safety of deferasirox for myocardial iron removal in transfusion dependent… 
Highly Cited
2011
Highly Cited
2011
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to prevent complications associated with… 
Highly Cited
2010
Highly Cited
2010
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Background Following a clinical evaluation of deferasirox (Exjade®) it was concluded that, in addition to baseline body iron… 
Highly Cited
2010
Highly Cited
2010
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
Cardiac iron overload causes most deaths in beta-thalassemia major. The efficacy of deferasirox in reducing or preventing cardiac… 
Highly Cited
2009
Highly Cited
2009
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1
To evaluate the effect of deferasirox in human myeloid leukemia cells, and to identify the moleclular pathways responsible for… 
Highly Cited
2007
Highly Cited
2007
The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate… 
Highly Cited
2007
Highly Cited
2007
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
Objectives/methods:  This 1‐yr prospective phase II trial evaluated the efficacy of deferasirox in regularly transfused patients… 
Highly Cited
2006
Highly Cited
2006
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron overload from blood… 
Review
2006
Review
2006
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation… 
Highly Cited
2006
Highly Cited
2006
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
BACKGROUND AND OBJECTIVES Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)